Jonathan Jones - Curasan AG Insider

Curasan AG -- Germany Stock  

EUR 1.18  0.06  5.36%

CFO

Mr. Jonathan Lloyd Jones was appointed as Chief Financial Officer of Neuralstem Inc. effective May 18 2015. Mr. Lloyd Jones has more than 25 years of corporate finance and business development experience. Mr. Lloyd Jones is a Chartered Accountant and holds a Masters of Business Administration from Wharton School of the University of Pennsylvania and a BSc from the University of Bradford
Age: 53  CFO Since 2015      
49 6027 40 900 51  http://www.curasan.de
Lloyd Jones has a background in corporate finance, particularly in licensing and partnering initiatives and in instituting financial infrastructure. From January 2013 until October 2014, he served as Chief Financial Officer of Columbia Laboratories . Prior to that, from 2011 to 2012, Mr. Lloyd Jones served as Chief Financial Officer and Vice President of Corporationrationrationrate Development at TetraLogic Pharmaceuticals, a venturebacked pharmaceutical company. Additionally from 2006 to 2010, Mr. Lloyd Jones served as Vice President, Finance, at TransMolecular, a privatelyheld clinical stage biotech company.

Management Efficiency

The company has return on total asset (ROA) of (15.5) % which means that it has lost $15.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (39.32) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 695 K in total debt with debt to equity ratio (D/E) of 10.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curasan AG has Current Ratio of 1.18 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Entity Summary

curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. Curasan AG operates under Healthcare Products classification in Germany and traded on Frankfurt Stock Exchange exchange. It employs 36 people.Curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 36 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Curasan AG to your portfolio

Top Management

Curasan AG Leadership Team
William Oldaker, Director
David Castaneda, Executive
Stanley Westreich, Director
Karl Johe, Chairman
Scott Ogilvie, Director
Catherine Sohn, Director, Ph.D
Richard Garr, CEO
Richard Daly, CEO, MBA
Sandford Smith, Director
Jonathan Jones, CFO

Stock Performance

Curasan AG Performance Indicators